The shape of things to come


Breaking news from the floor of ESCRS

In a breakfast meeting on the first morning of the show, Carl Zeiss Meditec presented its solutions for cataract, refractive and retina applications under its motto of 'creating what's to come'. The company aims to demonstrate its vision for the future and during the ESCRS will be displaying its MICS platform, Toric solution, FORUM ready and VISULAS Trion VITE.

Dr Ludwig Monz, CEO and President of Carl Zeiss Meditec, stressed the importance of the motto to the company and its goal of driving progress in medicine. He, stated that with the full range of products on offer, it was the aim to “make things work together and make a system out of it” so users can benefit from a complimentary but extensive ophthalmology portfolio. In addition to this he reported that live demonstrations were available from the show floor for visiting delegates.

The first product to be discussed was the Zeiss MICS Platform, which was split into four components; lenses, VISALIS - Phaco technology, OVDs and the BLUEMIXS 180 injector. IOLs have been long on the company's product portfolio and customers can find a wide range to suit a variety of needs. The VISALIS phaco technology is reported to offer dedicated phaco handpieces and fluidics capable of MICS enabling incisions of 1.8 mm and below incisions and good vacuum control. This in turn results in a lower risk of complication after surgery. OVDs need to be both cohesive and dispersive, Zeiss Meditec has combated this problem with the Twinvisc that contains both OVDs in separate compartments that are applied using the same device. The new BLUEMIXS 180 injector can accommodate a diverse range of preloaded MICS IOLs. This has been specifically designed for MICS procedures and all of the company's lenses will work with this instrument.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.